Slide 1: Schedule 14A Proxy Statement - Puma Biotechnology, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Conf
Slide 2: Slide 2
Slide 3: Puma issued the following investor presentation on January 7, 2016
On January 7, 2016, Puma Biotechnology, Inc. issued the following investor presentation.
Slide 4: Continued Focus on Developing Shareholder Value
Continued Focus on Developing Shareholder Value Investor Presentation January 2016
Slide 5: Puma's innovative breast cancer treatment products achieve significant milestones
Puma’s innovative breast SABCS published – treatment Reported cancer Experienced December of inproducts initial HER2-positive Lancet at 2015 data 11, Oncology, to Board CTRC-AACR from treat 2015and cancer the breast – Presented aPhase Management well cancer Puma San respected II trial additional Ant
Slide 6: Active, Engaged and Experienced Board
Puma directors, various enhance in other the was Oncology has roles, cancer who aanpartner Active, including possess care Drug for and Engaged Division anine chief well-diversified treatment years executive and at at the Experienced The a U.S. major current officer, range Food biotechnology Board of
Slide 7: Highly-Qualified Biotechnology, Management Team with Proven Track Record
Highly-Qualified Biotechnology, Phase Onyx HER HER2-positive positive Franchise Pharmaceuticals, IIIearly clinical stage metastatic Inc., Group trials Management breast which Leader, Richard Inc.breast cancer was Erin and Team P. responsible cancer, E. (only Bryce, Head Jones, with drug and of Puma’
Slide 8: ISS Recommends Shareholders Reject Eshelman's Proposals
ISS Recommends recommendation, thus prudent regarding lines far.” of business.” at“In the thislight current stage.” ISS Shareholders of Source: Puma’s makeup noted “Puma’s ISS that: recent ofProxy recent Reject the “Shareholder board board.” Advisory director Eshelman’s additions “Puma’s appointees
Slide 9: Glass Lewis Recommends Shareholders Reject Eshelman's Proposals
shareholders and Glass peers.” would the board Company’s accept Lewis prior seemingly “[M]ost the toconducted Recommends would this risk transparency. ofmisrepresent consent the characteristics be‘problematic well independent solicitation. Shareholders served Tohis the typically own supporting state
Slide 10: Egan-Jones Recommends Shareholders Reject Eshelman's Proposals
Egan-Jones “CONSENTING that Egan-Jones, the current Recommends Proxy Board THE Report and BLUE Shareholders management dated REVOCATION December Reject have28, theCARD Eshelman’s 2015. necessary Permission provided Proposals experience bytomanagement use Similarly and quotations expertise toisISS in
Slide 11: Proxy Mosaic's Analysis Is Problematic
Proxy Mosaic’s release Puma’s exceeds development report, Mosaic we of report published the clinical note exercise process was that Analysis trial strategic neither they price with data are isof sought respect plan including Problematic a$195.33 new and nor toplayer makes neratinib’s SEC obtained. (
Slide 12: Eshelman Has Never Met with the Company
Eshelman the this Company’s wasteful hasand Never good unproductive Met faithwith attempts the campaign. Company to understand 8 and has his No concerns, Understanding Eshelmanofnever the Company met withThe the Company and has attempted has repeatedly to engage demonstrated with Eshelman that he an
Slide 13: Eshelman and His Nominees Provide No Additional Benefit to the Company
Eshelman (substantive of that the they investment see andor noHis otherwise) value ofNominees the in Company’s the asaddition to Provide how shareholders, he of Noand Eshelman Additional his nominees the or Benefit his Board proposed willcannot toimprove the slate Company eventhe ofcontemplate direc
Slide 14: Eshelman's Consent Solicitation Has Been Expensive and Time-Consuming
Eshelman‘s stock consuming litigation solicitation. ownership related distraction Consent 10 and to the Solicitation prematurely to solicitation) our ongoing Has filing will Been efforts. abelawsuit approximately Expensive Theagainst Company andthe $1,000,000. Time-Consuming estimates Companythat Th
Slide 15: Eshelman Continues to Demonstrate a Lack of Integrity
Eshelman (which apparently that theywould have Continues toldrepresent refused several totoshareholders, Demonstrate approximately provide consent aorLack 1.0—1.5 led tothem Eshelman of Integrity million to believe, forEshelman shares) any that ofof Puma’s their Puma has shares. made largest stock.
Slide 16: Eshelman Continues to Demonstrate a Lack of Integrity (cont'd)
clinical trial included: Eshelman Fabrication Continues wasduring forced the to of todevelopment Demonstrate testify data at before one clinical of a Congress Lack the antibiotic site of Integrity (investigator regarding drug(cont’d) PPD’s Ketek convicted Eshelman’s for involvement theof treatment f
Slide 17: Eshelman Continues to Demonstrate a Lack of Integrity (cont'd)
Eshelman Continues to Demonstrate a Lack of Integrity (cont’d) • A whistleblower from PPD, Ann Marie Cisneros – a clinical trial associate for PPD – testified that she sent evidence of fraud to PPD management, which was ignored • “[b]ased upon what I observed and learned in monitoring the Kirkman-Ca
Slide 18: Eshelman's Proposed Changes Are Not in the Best Interests of Shareholders
Eshelman’s experienced business and management Eshelman Proposed and board 14hasChanges size not come is appropriate areforth Not with in the forany Puma’s Best value Interests stage enhancing of of development Puma proposals Shareholders Eshelman Board and Puma seeks management hasboard a strong re
Slide 19: Company urges Puma shareholders to revoke their consent on the BLUE Revocation Card
For the foregoing reasons, the Company urges Puma shareholders to Revoke their consent from the Eshelman Consent Solicitation on the BLUE Revocation Card 15
Slide 20: Forward-Looking Statements
Forward-Looking plans clinical phrases. statements. that conducting conduct from unduewe time with reliance have trials our All to respect and These forward–looking clinical time, no and on enrolling product announcement statements these Statements to including trials ourforward-looking revenue regu
Slide 21: Additional Information and Where You Can Find It
Additional the names document with shareholder THERETO) willconsent be theof able SEC the isInformation solicitation entitled to AND available Company’s inobtain, connection ANYtofree deliver by and OTHER directors Dr. ofWhere with charge, charge aFredric written the RELEVANT and You consent atcopie